Welcome! Thank you for visiting the Diurnal website. It is an honour for me to introduce you to our company and ethos and to emphasise our on-going commitment to developing high-quality hormone therapeutics for patients with chronic endocrine conditions.

At Diurnal, patients are at the forefront of everything we do. Since our inception in 2004, our mission has been clear: to address crucial unmet patient and clinical need in the endocrine field and to deliver the best health outcomes to improve patients’ quality of life.

How are we achieving this? By continuing to harness and channel the passion, knowledge and expertise of our team to create and develop a unique and highly specialised pipeline of products that focus on meeting patient needs.

In 2018, the European Commission approved Diurnal’s first product - Alkindi® as replacement therapy of adrenal insufficiency in patients aged from birth to 18 years.  Alkindi® was subsequently launched in Germany and the UK and its commercial roll-out will continue across Europe during 2019. 

The approval and commercialisation of Alkindi® is a credit to the hard work of patients, investigators, the Diurnal team and our collaborators that helped develop Alkindi®, and demonstrates that we can successfully develop and commercialise first-in-class medicine formulations to treat diseases of cortisol deficiency.

2019 promises to be a pivotal year in the evolution of Diurnal, with the anticipated feedback from the European Medicines Agency on data generated in our pivotal Phase III study in congenital adrenal hyperplasia of our second product candidate, Chronocort®, and subsequent progression into adrenal insufficiency.  

Through our unfaltering commitment and drive, my ambition is for Diurnal to be a global leader in specialist endocrine products. I promise that Diurnal will continue to strive to deliver products of the highest quality and efficacy for patients with chronic endocrine conditions, to enable them to lead healthier, happier and more active lives.

It is my hope that your first visit to our website is the first all-important step on that road.

Martin Whitaker
Chief Executive Officer